The effectiveness and safety of the RSVpreF vaccine when used in the elders
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by An Duc Thien Le |
Posted on May 15th, 2023
|
RSV infection in the elderly is especially worrisome because it can be exacerbated by coexisting conditions. Currently, there has not been any vaccine approved for this demographic. The pharmaceutical company Pfizer had funded a study that investigated the effectiveness of the bivalent RSV prefusion F protein−based (RSVpreF) vaccine in preventing infection in the elderly.
The phase 3 clinical trial included 34,284 elderly adults who were older than 60 years old. These participants were randomly assigned to receive an intramuscular injection of either placebo or 120 micrograms of the vaccine. Follow up was performed for 311 days, and the researchers found that the RSVpreF vaccine has an effective rate of 66.7% at preventing RSV infection with two symptoms in the elderly, and the efficacy was 85.7% in infection with diseases with at least 3 symptoms. In terms of safety, the rate of local reaction was 5% higher in the group vaccinated with RSVpreF; however, there was no difference in the rate of systemic adverse events.
The phase 3 clinical trial included 34,284 elderly adults who were older than 60 years old. These participants were randomly assigned to receive an intramuscular injection of either placebo or 120 micrograms of the vaccine. Follow up was performed for 311 days, and the researchers found that the RSVpreF vaccine has an effective rate of 66.7% at preventing RSV infection with two symptoms in the elderly, and the efficacy was 85.7% in infection with diseases with at least 3 symptoms. In terms of safety, the rate of local reaction was 5% higher in the group vaccinated with RSVpreF; however, there was no difference in the rate of systemic adverse events.